9 April 2020 in I.P. Pavlov Russian Medical Biological Herald
Apoptosis is recognized as a programmed cell death controlled by genetic mechanisms and required for normal existence of an organism. Its main task is elimination of defective or mutant cells. The particles of dead cells are engulfed by macrophages with no development of inflammatory reaction. Apoptosis actively participates in embryogenesis, cellular homeostasis, elimination of tumor cells, and may be divided to three phases: signal, effector, and degradation. Its main components are cytoplasmic proteases caspases. Caspases exist in the cytoplasm in inactive condition in the form pf procaspases. Being activated, they break down to subunits. Proteins of Bcl-2 family are active participants of the mitochondrial pathway of apoptosis. They influence permeability of the outer membrane of mitochondria. Disorders in the mechanisms of apoptosis underlie many diseases including ischemic lesions, autoimmune disorders, malignant neoplasms. The ability to influence survival or death of cell is known to possess enormous therapeutic potential. At present, active research is under way to study signal pathways that control cell cycle and apoptosis. The article discusses the mechanisms participating in death of vascular endothelium and smooth muscle cells, potential role of apoptosis in atherosclerosis is also described.
30 June 2023 in Nauka Molodykh (Eruditio Juvenium)
RURyazan State Medical University
Ryazan State Medical University
INTRODUCTION: An analysis of publications of domestic and foreign literature was carried out and a review on endothelial dysfunction in patients with varicose saphenous veins of the lower extremities was presented. We searched Elibrary and PubMed biomedical publication databases for the required information for the last 5 to7 years using keywords: varicose saphenous veins of lower extremities, endothelial dysfunction, endothelial dysfunction markers. Today, diseases of the cardiovascular system occupy a leading position with the most common of them being chronic venous disease that affects 10% to 30% of the adult working-age population of the Russian Federation. Varicose veins cover a wide range of conditions from minor telangiectasia to pronounced varix dilatation of veins and severe venous insufficiency with venous ulcers. The endothelium is not only a barrier between blood and tissues, but also a kind of endocrine organ that produces a number of vasoactive substances that maintain homeostasis and perform, depending on environmental conditions, both an antithrombotic, anti-inflammatory, vasodilating effects, and a procoagulant, inflammatory and vasoconstrictive effects. Endothelial dysfunction is considered by many domestic and foreign authors as the main link in the development and progression of many diseases, including varicose veins. CONCLUSION: Determination of the dynamics of some markers of endothelial dysfunction and connective tissue dysplasia in patients with varicose saphenous veins of the lower extremities is a priority direction in prevention of disease progression. Despite ongoing research, many aspects of the pathogenesis of varicose veins of the lower extremities are still unclear. Further study of the basic factors of the development and progression of the pathology of the venous system is important for elaboration of algorithms for effective pathogenetic correction and improving the quality of life in patients with varicose veins of the lower extremities.
15 December 2021 in I.P. Pavlov Russian Medical Biological Herald
Introduction: As with many other surgical interventions, the implantation of a pacemaker may be associated with adverse outcomes in the immediate or distant period. The search for probable risk factors of adverse outcomes may promote the development of effective and safe management methods of patients with pacemaker postoperatively. One of the important directions in this field is the investigation of the effect of pacemaker implantation on the hemostasis system of these patients. Aim: To evaluate the effect of the implantation of dual-chamber pacemaker on the hemostasis system of patients with different kinds of bradyarrhythmias and to determine probable risk factors for unfavorable outcomes in this groupof patients. Materials and methods: The study was performed with the financial support of the Russian Foundation for Basic Research within the Scientific Project No. 19-315-90109. The prospective study (ClinicalTrials.gov ID, NCT04499612) enrolled 61 patients (men, 45.9%) with a mean age of 71.5 8.8 years. The groupwho received surgical treatment included 23 patients with atrioventricular (AV) block and 25 patients with sick sinus syndrome (SSS), and the groupwith conservative treatment included 13 patients with AV blocks and SSS, but without indications for pacemaker implantation. Anticoagulant therapy was given to one patient with AV block, 12 patients with SSS, and five patients with conservative therapy. All the remaining patients received antiplatelet therapy. The surgical groupunderwent ultrasound examination of the veins of the upper and lower extremities and sampling of peripheral venous blood before and 7 days after pacemaker implantation to determine the level of fibrinogen (FI) and activity of blood coagulation factors VIII (FVIII) and IX (FIX), antithrombin III (AT III), and protein C. In the conservative group, a similar examination was conducted only on inclusion in the study. Results: In patients with AV block, a significant increase in blood fibrinogen was noted at 7 days after surgery (р=0.042). In the intergroupcomparison, the activity of AT III after the implantation was higher in the surgical groupthan in the conservative group(р=0.018 and р=0.006, respectively). After surgery, the activity of FVIII and FIX was lower in patients with SSS on anticoagulant therapy than in patients with antiplatelet therapy (р=0.048 and р=0.015, respectively). Based on the receiver operating characteristics analysis, the risk factors for lethal outcomes were reduced activity of AT III in patients with AV block and increased activity of FIX in patients with SSS. Conclusions: The balance of the hemostasis system in patients with AV blocks on antiplatelet therapy was shifted toward hypercoagulation within at least 7 days after pacemaker implantation. The use of anticoagulants in patients with SSS caused a shift toward hypocoagulation. The reduced activity of AT III in patients with AV block and increased activity of FIX in patients with SSS are prognostic factors for lethal outcomes.
5 August 2021 in Vascular Specialist International
Roman E. Kalinin, Igor A. Suchkov, Nina D. Mzhavanadze, Olga N. Zhurina, Emma A. Klimentova, and Vladislav O. Povarov. Vasc Specialist Int 2021;37:. https://doi.org/10.5758/vsi.210010
27 December 2024 in Journal of Venous Disorders
Objective. To study the effect of sulodexide on endothelial dysfunction and quality of life in patients with varicose veins. Material and methods. The study included 93 patients with varicose veins CEAP class C2-C3. They were divided into 4 groups: group 1 — compression hosiery; group 2 — sulodexide 250 LE 2 times a day; group 3 — endovenous laser ablation; group 4 — endovenous laser ablation followed by sulodexide therapy. We analyzed serum E-selectin, MCP-1, VEGF, MMP-2 and MMP-9 as markers of endothelial dysfunction and vein-specific inflammation. Quality of life changes were assessed using the CIVIQ-20 and SF-36 questionnaires. Results. E-selectin decreased by 24% after 2 months in the 1st group (p=0.004). In the 2nd group, E-selectin, MCP-1, MMP-2 and MMP-9 significantly decreased (p=0.001, p<0.001, p<0.001 and p=0.04, respectively), while VEGF did not change (p=0.73). E-selectin, MCP-1 and MMP-9 decreased in the 3rd group. In the 4th group, all indicators decreased after complex treatment. After 2-month therapy, QoL improved in all groups (p<0.05), except for the first group (CIVIQ-20 questionnaire, p=0.73). Conclusion. Sulodexide therapy, especially after invasive treatment, improves the quality of life, reduces serum markers of endothelial dysfunction and vein-specific inflammation.
16 July 2023 in I.P. Pavlov Russian Medical Biological Herald
INTRODUCTION: A new coronavirus infection (NCI) is characterized by catastrophic coagulopathy with development of thrombotic and hemorrhagic complications. The choice of an optimal anticoagulant in these patients remains an important issue. AIM: To evaluate risk factors for venous thromboembolic complications (VTEC), effectiveness and safety of different variants of anticoagulant therapy (ACT) in patients with NCI. MATERIALS AND METHODS: A prospective study was conducted that involved 370 patients with NCI: group 1 patients who received low molecular weight heparin (LMWH) 190 people, group 2 patients who received unfractionated heparin (UFH) 123 people, group 3 patients who took direct oral anticoagulants (DOAC) 57 individuals. Clinical and anamnestic data, frequency of thrombotic and hemorrhagic complications were evaluated. The study was approved by the Local Ethics Committee and was registered on ClinicalTrials.gov. platform. RESULTS: The existence of chronic venous diseases increases the risk of development of venous thromboembolism (VTE) in patients with NCI 6.433 times (95% confidence interval (CI) 2.16719.093)) (р = 0.001), use of UFH instead of LMWH or DOAC 3.542 times (95% CI 1.14910.916) (р = 0.028), use of artificial lung ventilation (ALV) 5.925 times (95% CI 2.03417.26) (р = 0.001), high D-dimer level 2.024 times (95% CI 1.2313.33) (р = 0.005). The level of C-reactive protein and ferritin decreased in all patients in the course of treatment for NCI, with the lowest levels in patients receiving LMWH (С-reactive protein 5.8 (1.715.0) mg/l, р = 0.004; ferritin 364 (324497) g/l, р = 0.001). Lower fibrinogen levels were recorded in patients of group 1 compared to groups 2 and 3 (2.43 (1.93.52) g/l versus 3.37 (2.84.92) g/l and 4.1 (2.85.25) g/l, respectively, р = 0.002). A high frequency of pulmonary embolism with unspecified source was recorded in patients receiving UFH 11.4% of cases, with this, the frequency of using ALV in the group with UFH was evaluated as high 21% of cases. CONCLUSION: Risk factors of VTEC in patients with NCI are both factors typical of VTEC in general (obesity, chronic vein diseases, elevated D-dimer level), and factors specific of NCI (ALV, hypoventilation). Effective and safe anticoagulants in this group of patients are LMWH that demonstrated low frequency of development of VTEC and of hemorrhagic complications.